Holen Sie sich die Stockscreener-App
71.87
4.87%
3.24
Schlusskurs vom Vortag:
$68.63
Offen:
$68.55
24-Stunden-Volumen:
109.51K
Relative Volume:
0.79
Marktkapitalisierung:
$479.21M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.12M
KGV:
-31.25
EPS:
-2.3
Netto-Cashflow:
$-6.82M
1W Leistung:
-4.19%
1M Leistung:
-21.39%
6M Leistung:
+119.04%
1J Leistung:
+178.76%
1-Tages-Spanne:
$68.37
$72.72
1-Wochen-Bereich:
$64.25
$75.21
52-Wochen-Spanne:
$21.00
$105.00
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Firmenname
Monopar Therapeutics Inc
Sektor
Branche
Telefon
(847) 388-0349
Adresse
1000 SKOKIE BLVD SUITE 350, WILMETTE
Vergleichen Sie MNPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
71.71 | 458.63M | 0 | -7.12M | -6.82M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.73 | 115.75B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.35 | 80.71B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.12 | 52.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.74 | 52.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.60 | 37.29B | 447.02M | -1.18B | -906.14M | -6.1812 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-14 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-11-10 | Eingeleitet | Leerink Partners | Outperform |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-09-09 | Eingeleitet | BTIG Research | Buy |
| 2025-09-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-08-26 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-19 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-01-10 | Eingeleitet | Piper Sandler | Overweight |
| 2024-10-11 | Eingeleitet | Rodman & Renshaw | Buy |
| 2021-01-28 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Monopar Therapeutics Inc Aktie (MNPR) Neueste Nachrichten
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 - Zacks Investment Research
Independent Director Arthur Klausner Sold A Bunch Of Shares In Monopar Therapeutics - simplywall.st
What dividend safety score for Monopar Therapeutics Inc. stockStop Loss & AI Powered Buy and Sell Recommendations - Улправда
Major Insider Move Shakes Up Investor Watch on Monopar Therapeutics - TipRanks
Is Monopar Therapeutics Inc. stock a safe haven assetJuly 2025 Summary & Accurate Intraday Trading Signals - Улправда
Insider Sell: Arthur Klausner Sells Shares of Monopar Therapeuti - GuruFocus
Monopar Therapeutics Insider Sold Shares Worth $343,889, According to a Recent SEC Filing - marketscreener.com
Will Monopar Therapeutics Inc. stock gain from strong economyWeekly Stock Report & Weekly High Conviction Ideas - DonanımHaber
Why retail investors favor Monopar Therapeutics Inc. stock2025 Momentum Check & Community Shared Stock Ideas - DonanımHaber
Why Monopar Therapeutics Inc. stock appeals to analystsJuly 2025 PreEarnings & High Return Stock Watch Alerts - DonanımHaber
Is Monopar Therapeutics Inc. (1IY0) stock a good hedge against inflation2025 Retail Activity & Technical Buy Zone Confirmation - DonanımHaber
How cyclical is Monopar Therapeutics Inc. (1IY0) stock compared to rivalsDip Buying & High Conviction Trade Alerts - Улправда
Treasury Yields: How cyclical is Monopar Therapeutics Inc. (1IY0) stock compared to rivalsInsider Buying & Community Verified Trade Signals - Улправда
(MNPR) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Monopar Therapeutics (NASDAQ:MNPR) Rating Increased to Hold at Wall Street Zen - Defense World
Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Recommendation of “Buy” by Brokerages - Defense World
Monopar Therapeutics (NASDAQ:MNPR) Upgraded at Wall Street Zen - Defense World
Aug Catalysts: How interest rate cuts could boost Monopar Therapeutics Inc stockGap Up & High Accuracy Trade Alerts - moha.gov.vn
Monopar Therapeutics (NASDAQ:MNPR) Shares Up 6.3%Should You Buy? - MarketBeat
Monopar Therapeutics (NASDAQ:MNPR) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Will Monopar Therapeutics Inc. stock benefit from commodity prices2025 Winners & Losers & Safe Swing Trade Setup Alerts - Newser
Will Monopar Therapeutics Inc. (1IY0) stock rise with strong economyShare Buyback & Free Weekly Watchlist of Top Performers - Newser
How Monopar Therapeutics Inc. (1IY0) stock behaves in tightening cyclesJuly 2025 Setups & Consistent Growth Equity Picks - Newser
Is Monopar Therapeutics Inc. (1IY0) stock a safe buy pre earningsJuly 2025 Gainers & Verified Technical Signals - Newser
How (MNPR) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Monopar Therapeutics (NASDAQ:MNPR) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
How Monopar Therapeutics Inc. (1IY0) stock correlates with oil markets2025 Investor Takeaways & Reliable Volume Spike Alerts - Newser
Can Monopar Therapeutics Inc. (1IY0) stock stage a strong rebound this quarterRecession Risk & Risk Controlled Stock Alerts - Newser
Is Monopar Therapeutics Inc. (1IY0) stock worth buying before Fed actionMarket Activity Report & High Accuracy Investment Signals - Newser
Is Monopar Therapeutics Inc. stock a safe investment in uncertain markets2025 Support & Resistance & Entry Point Strategy Guides - moha.gov.vn
Monopar Therapeutics Inc Stock Analysis and ForecastContrarian Investment Ideas & Free Rapid Portfolio Appreciation - earlytimes.in
Monopar Therapeutics (NASDAQ:MNPR) Shares Down 4%Time to Sell? - MarketBeat
Monopar Therapeutics (NASDAQ:MNPR) Shares Gap UpHere's What Happened - MarketBeat
Monopar Therapeutics Unveils Promising Phase 2 Study Results - MSN
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments - ADVFN
Trading Systems Reacting to (MNPR) Volatility - news.stocktradersdaily.com
Monopar Therapeutics Inc. (MNPR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is There An Opportunity With Monopar Therapeutics Inc.'s (NASDAQ:MNPR) 46% Undervaluation? - simplywall.st
Is Monopar Therapeutics Inc. (NASDAQ:MNPR) Trading At A 46% Discount? - Yahoo Finance
Monopar Therapeutics Shares Surge in Volatile Friday Session - Ad-hoc-news.de
Is Monopar Therapeutics Inc. stock a top momentum playTrade Signal Summary & Safe Entry Trade Signal Reports - newser.com
How geopolitical tensions affect Monopar Therapeutics Inc. stock2025 Institutional Moves & Growth Focused Investment Plans - newser.com
Will Monopar Therapeutics Inc. stock outperform Dow Jones indexMarket Volume Report & High Win Rate Trade Tips - newser.com
Why Monopar Therapeutics Inc. (1IY0) stock could be top winnerJuly 2025 Rallies & Long-Term Investment Growth Plans - newser.com
Why millennials buy Monopar Therapeutics Inc. (1IY0) stock2025 Support & Resistance & Free Fast Gain Swing Trade Alerts - newser.com
How Monopar Therapeutics Inc. (1IY0) stock expands through international marketsJuly 2025 Market Mood & Momentum Based Trading Ideas - newser.com
Can Monopar Therapeutics Inc. stock sustain market leadershipJuly 2025 Price Swings & Verified Trade Idea Suggestions - newser.com
Finanzdaten der Monopar Therapeutics Inc-Aktie (MNPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Monopar Therapeutics Inc-Aktie (MNPR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| KLAUSNER ARTHUR J | Director |
Dec 18 '25 |
Sale |
67.15 |
5,121 |
343,889 |
8,762 |
| Tactic Pharma LLC | 10% Owner |
Sep 24 '25 |
Sale |
63.61 |
550,229 |
34,999,957 |
272,026 |
| Tsuchimoto Kim R | Director |
Jul 14 '25 |
Sale |
40.00 |
8,904 |
356,171 |
11,486 |
| STARR CHRISTOPHER M | Director |
Jul 14 '25 |
Sale |
40.00 |
16,800 |
672,020 |
5,173 |
| Robinson Chandler | Chief Executive Officer |
Jul 14 '25 |
Sale |
40.00 |
16,800 |
672,020 |
73,472 |
0.13%
3.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):